Cancer Research

Dr. Clay Siegall of Seattle Genetics Develops ADCETRIS for Cancer Treatment

For centuries, genetics study has been the core benchmark for patient’s treatment. The study of genetic variation in patients mainly contributes to the final diagnosis. With a correct diagnosis, comes the right treatment. It is, therefore, vital for physicians to understand genetic mutation while administering treatment. That is why Dr. Clay Siegall of Seattle Genetics is cheered for his massive contribution to the genetic study. The co-founder of Seattle Genetics started his career in the company in 1998. As the serving president and chief executive officer, Clay has always chaired the board in decision making. With his leadership skills, Clay Siegall has seen Seattle Genetics develop innovative practices towards disease treatment.




Recently, the company announced its position in generating antibody conjugates. These antibodies are known as ADCs. After the development of ADCs, he pushed for the treatment to be certified by FDA in 2011. This was the first FDA approval of ADCs. Clay’s leadership at Seattle Genetics extends to the collaboration of the company with Takeda Pharmaceuticals. With the partnership, Seattle Genetics has become prominent. ADC is currently approved in over 65 countries. Clay’s leadership at Seattle Genetics is vastly advancing the company’s distribution of ADCs.


Clay’s Profile


Clay Siegall is an executive scientist and researcher. He focuses his studies on genetic mutation and assimilation. The alumnus of George Washington University was appointed a board member of Mirna Therapeutics in 2013. This was because of his profound commitment to finding treatment through genetic study. While forming Seattle Genetics in 1998, his core agenda was to provide treatment for cancers like lymphoma and other diseases. He has ensured this by partnering with major stakeholders in disease control centers to develop treatment solutions.


Additionally, his experience roots from the vast experience in previous institutions. He worked at Bristol-Myers Squibb Pharmaceuticals from 1991 to 1997. He also worked at the National Cancer Research Institute and National Health Institute from 1988 to 1991. He is a member of the board in several companies including Alder BioPharmaceuticals, Ultragenyx Pharmaceutical and Washington Roundtable. It is evident that Clay Siegall is committed to finding treatment solutions for cancer and other diseases through genetic study.

Eric Lefkofsky: From Tech Entrepreneurship to Cancer Research

Technology continues to be the force that shapes the world today. At the center are the tech entrepreneurs whose innovations impact the economy and job creation, health. Education, and society in general. Some of these tech entrepreneurs, such as Eric Lefkofsky (, have taken involvement to the next level by directly investing in their communities and creating start-ups to find solutions to recurring social and health issues.

Lefkofsky recently co-founded Tempus, a biotechnology start-up. This recent undertaking reflects a philanthropic advocacy combined with his tech background. Lefkofsky and his family has been known to contribute millions of dollars for cancer research.
Since starting Tempus, Eric Lefkofsky and his team has been involved in cancer research by building an operating system to battle the disease. Tempus has been gathering data on cancer genomes and tracking driver genes that can cause the disease. Information culled from the research will be used to develop personalized care and treatment for patients.

His social media presence shares insights on Tempus’ work and how important this current pursuit is in revolutionizing care for cancer patients and finding innovations in treatment. In a recent Tweet he said, “We have invested hundreds of billions of dollars to better understand cancer drivers but have only mapped a small percentage of the genome.”

He has been involved in other philanthropic endeavors though the Lefkofsky Family Foundation, whose purpose is “to advance high-impact programs, initiatives and research that enhance the quality of human life in the communities that they serve.” Lefkofsky recently donated $1 million to the new Ability Institute of RIC in Chicago. The foundation also funded the Academy for Urban School Leadership’s “Success Project.” The nonprofit organization works with lower performing schools in the Chicago area, seeking to assist middle-school students to successfully transition to high school.

Aside from contributing to the nonprofit community in Chicago, Lefkofsky and his wife Liz has signed the Giving Pledge, a campaign encouraging the world’s wealthiest to commit a huge chunk of their assets to support philanthropic causes and address urgent global issues.

Leflkofsky authored “Accelerated Disruption: Understanding the True Speed of Innovation” (Easton Studio Press, 2007). As described in his book, the concept of accelerated disruption is about “business development moving at the speed of the next technological advancement,” with the basic premise that “those businesses that can understand and control the forces of technology will thrive in the coming years. Those that cannot will find themselves displaced.”

Leflkofsky himself is no stranger to innovation and technology. He has made an impact in the tech industry with an impressive portfolio that includes founding Groupon, one of the most successful e-commerce start-ups, and Lightbank, a venture capital group investing in disruptive technology. He also co-founded Uptake Technologies, Mediaocean, Echo Global Logistics, and InnerWorkings.

Lefkofsky attended the University of Michigan Law School, earning a juris doctor in the 90s. He also served as an adjunct professor at the University of Chicago Booth School of Business where he lectured on “Building Internet Start-Ups” and mentored aspiring tech entrepreneurs. He also served as a guest professor at Northwestern University’s Kellogg School of Management where he talked about “Technology-Enabled Innovation.”